In a recently published short report in Acta Oncologica, the IMPRESS team presents the first preliminary results from IMPRESS-Norway. The report covers all patients who received treatment between April 2021 and October 2023. A total of 358 patients have been offered treatment in IMPRESS-Norway during this period, and of these, 186 have started treatment. The …
The first results from IMPRESS-Norway have been published! Read More »
On October 20-24, several from the IMPRESS-Norway team gathered in Madrid for the ESMO 2023 congress. The European Society for Medical Oncology (ESMO) has more than 34 000 members across 170 countries, and the annual conference is an excellent arena to learn more about news/results from clinical trials and developments within cancer care, from prevention and …
ESMO 2023 and IMPRESS-Norway activities in Madrid – October 20-24 Read More »
The PRIME-ROSE kick-off took place in Oslo on September 19-20 and gathered around 70 participants from different partners across Europe PRIME-ROSE builds on a bottom-up, investigator-initiated family of clinical trials in precision cancer medicine, including IMPRESS-Norway, which have successfully brought up inclusion rates to offer additional lines of treatment and provide patient benefit. PRIME-ROSE will …
Official Opening of the Horizon EU Cancer Mission PRIME-ROSE project Read More »
IMPRESS-Norway has been open for inclusion for over two years and so far more than 1000 patients have had their tumor sequenced through InPreD and over 200 patients have been offered a new treatment. The study is dynamic in the way that new companies and new drugs can be added to the study all the …
Åslaug Helland is awarded the prestigious prize for her excellent molecular and clinical research, particularly on lung cancer diagnosis and treatment and for her efforts to introduce precision oncology for all types of cancer in Norway. The prize, one million NOK, will be presented by HM King Harald V in a ceremony in Oslo on …
Åslaug Helland receives King Olav V’s Prize for Cancer Research 2023 Read More »
PRIME-ROSE – A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission The European Commission on 24 April 2023 approved the project Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials, PRIME-ROSE. The project will officially start 1 July 2023 and is funded by the European Commission Horizon Europe Mission on …
IMPRESS part of a European network of clinical trials supported by the EU Read More »
All cancer patients in Norway who no longer benefit from standard treatment has the right to be considered for inclusion into a clinical trial. As part of this, patients will be offered comprehensive genomic profiling of their tumor. The regional health authorities in Norway decided in 2020 to establish an infrastructure for precision diagnostics (InPreD) …
InPreD at Haukeland University Hospital is open for business! Read More »
We have previously reported that the Regional Health Organizations have approved the opening of the first expansion cohort in IMPRESS-Norway (read more here). Recently, AstraZeneca and IMPRESS-Norway have also entered into an agreement which ensures support for the opening of the first expansion hospital. All the necessary approvals are now in place and the expansion …
The first expansion cohort is ready for inclusion Read More »
The international cancer conference ASCO was held in Chicago this weekend. ASCO is one of the most important cancer conferences in world where the latest in cancer research is presented. The conference is also an important meeting place and all the major pharmaceutical companies are represented. Recruitment of new drugs to IMPRESS Recruitment of more …
The precision cancer medicine ecosystem established in Norway and the ongoing implementation in the health care system are unique in an international context. Our experiences, successes and results are of great interest to the international community. The description of the entire ecosystem was therefore published in Nature Medicine today. – This publication is a recognition of the …
Description of the Norwegian Precision Medicine Initiatives published in Nature Medicine Read More »